Venus Remedies (NSE:VENUSREM, BOM:526953) has secured exclusive in-licensing rights from UK-based anti-infectives specialist Infex Therapeutics to develop and commercialize MET-X in India, according to a Tuesday filing to the Indian stock exchanges.
Under the terms of the agreement, Venus Remedies will begin with the first phase involving healthy volunteers in lndia, evaluating MET-X in combination with meropenem.
Following this, the focus will shift to the second and third phase trials targeting drug resistant complicated urinary tract infections in prevalent hospital settings.
Shares of the company were up 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.